#China #Shanghai #Orphalan #Wilson Disease #Ke Pei Ou

Orphalan's Groundbreaking Launch in China

Orphalan, a leader in orphan drug development, has marked a significant milestone by introducing its innovative treatment for Wilson's disease, named "Ke Pei Ou" (科佩欧®), in China. This momentous event not only makes Orphalan the first European pharmaceutical company to enter the Chinese market with an orphan drug but also opens up new avenues for patient care in a territory previously lacking effective treatments for this rare genetic condition.

A Collaborative Effort for Patient Access

The launch of "Ke Pei Ou" (科佩欧®) has been made possible through a strategic partnership with SPH Kyuan Trade, a prominent pharmaceutical distributor in China operating as a subsidiary of Shanghai Pharma Group. Together, they aim to enhance patient access to this essential therapy, which addresses the significant challenges faced by those suffering from Wilson's disease.

Wilson's disease is a serious genetic disorder that impairs the body's ability to process copper, leading to potentially severe neurological and liver damage if left untreated. Traditional treatments, primarily based on penicillamine, are often poorly tolerated by many patients, creating an urgent need for alternative therapies. Orphalan's product, trientine tetrahydrochloride, presents a new option that can significantly benefit patients who had few options before.

The Impact of Trientine Tetrahydrochloride

The approval of "Ke Pei Ou" (科佩欧®) by the National Medical Products Administration (NMPA) in China is noteworthy, as it is the first trientine-based treatment to receive such recognition in the country. Prior to this, Orphalan's product was already available in over 20 countries, marketed as Cuprior® in Europe and Cuvrior® in the United States. With its launch in China, it is expected to change the life of many patients historically limited in their treatment options.

Strengthening Local Presence in the Chinese Health Sector

In a bid to ensure the successful integration of "Ke Pei Ou" (科佩欧®) within the Chinese healthcare landscape, Orphalan has opened a local office in Shanghai. It has appointed Grace Li as General Manager, tasked with spearheading initiatives to engage key healthcare professionals, promote access to vital clinical data, and provide essential education on the management of Wilson's disease. This approach underscores Orphalan's commitment to tailoring its outreach to meet the needs of both healthcare providers and patients in China.

A Major Leap in Orphalan's Global Strategy

Orphalan's entry into the Chinese market symbolizes a strategic leap in its global mission to serve patients afflicted by rare diseases. As the company continues to establish itself within this highly competitive and regulated environment, it is poised to redefine patient access and embrace its role as a frontrunner in orphan drug innovation.

Dr. Naseem Amin, CEO of Orphalan, emphasized the significance of this launch, stating, "This is more than just a market expansion; it represents a breakthrough for rare disease patients in China. Our partnership with SPH Kyuan Trade is pivotal to our mission and reflects our dedication to revolutionizing access to care for those in need."

As Orphalan advances its core principles of innovation and excellence, it remains steadfast in its goal of ensuring that patients across China can benefit from cutting-edge treatments like "Ke Pei Ou" (科佩欧®). This launch not only highlights Orphalan's commitment to transforming the landscape of orphan drug development but also sets a new standard for patient accessibility in healthcare.

About Orphalan

Founded in 2011 and headquartered in Paris, Orphalan is dedicated to developing and providing innovative solutions for those suffering from rare diseases. The company collaborates with the global scientific community to create evidence-based treatments in areas where patient needs are unaddressed. With the widening of its distribution horizon to over 20 countries, its potent therapies continue to make waves in the realm of rare disease care.

For further inquiries about its products or partnerships, visit Orphalan's official website at www.orphalan.com. Follow them on LinkedIn for the latest updates on their groundbreaking work in the orphan drug industry.